Op-Ed: How Rethinking Hospital Access Can Solve the American Drug Shortage

For more than a decade, drug shortages have been treated as a manufacturing problem.

When shortages occur, the conversation usually turns to plant shutdowns, quality observations, supply concentration, or pricing pressure. These factors matter. However, they do not fully explain why shortages continue to disrupt care even when demand signals are visible and supply exists somewhere in the system.

What is often overlooked is how medicines are allocated, prioritized, and delivered to hospitals once constraints emerge. In practice, many shortages are not only about how much product is made, but about how effectively access is managed under stress.

If the United States is serious about reducing the real‑world impact of drug shortages, the industry must rethink hospital access as a system, rather than viewing manufacturing alone as the bottleneck.

How Do Drug Shortages Impact Hospital Operations and Patient Care?

From a hospital’s perspective, shortages do not appear as abstract supply chain events. Instead, they show up as missed doses, last‑minute substitutions, treatment delays, and hours of staff time spent tracking availability.

What Is The Role of 483‑Driven Disruptions?

Regulatory observations, including FDA 483 findings, offer an important example. They are often discussed as compliance events, but their downstream effects on supply continuity are well understood across the industry.

Competitor disruptions following such events are rarely invisible. What varies is how quickly organizations translate that information into action. Without execution infrastructure, these signals remain informational rather than operational.

When the system lacks a defined pathway from signal to decision, organizations react only once shortages become visible at the hospital level. By then, the opportunity to prevent disruption has passed.

Why Do Lower‑Tier Hospitals Feel the Impact First?

Nowhere are these gaps felt more acutely than in smaller and lower‑tier hospitals.

Large academic centers and major integrated delivery networks often have multiple sourcing options, stronger purchasing leverage, and dedicated resources to manage disruption. Smaller hospitals frequently do not.

During periods of constrained supply, traditional allocation and prioritization approaches—often based on historical volume or commercial importance—can unintentionally disadvantage these institutions. The result is earlier service degradation, higher substitution burden, and increased clinical and operational strain.

This is not an equity issue caused by intent. It is a design issue caused by static decision logic operating in a dynamic environment.

Why Are Current Industry Solutions Not Working?

The pharmaceutical industry has made significant investments to address shortages. Forecasting has improved. Data availability has expanded. Advanced analytics and AI models increasingly detect risk earlier than before.

Yet outcomes have not improved at the same pace.

The core issue is fragmentation.

Most organizations still operate with disconnected decision layers. Supply teams manage capacity and allocation. Commercial teams plan growth and account focus. Access teams manage coverage and contracting. Field teams execute based on static priorities.

Each function may perform well individually. However, when volatility hits, decisions are made sequentially rather than as a coordinated system.

Early signals, such as competitor disruptions following regulatory events or quality observations, often remain informational. They do not automatically trigger changes in allocation logic, account prioritization, or field focus. By the time hospitals feel the impact, the opportunity to prevent disruption has already closed.

Dashboards explain what happened. They rarely determine what should happen next.

Can Treating Hospital Access as Execution Infrastructure Solve the Drug Shortage Problem?

To reduce the impact of shortages, hospital access must be managed as “Execution Infrastructure” rather than as a downstream commercial activity.

Execution infrastructure is the system that sits between strategy and action. It connects demand signals, supply constraints, access realities, and account‑level urgency into a “single dynamic decision environment”. Most importantly, it defines how priorities change when conditions change.

In this model, early risk signals trigger predefined decision logic. Allocation rules adjust dynamically rather than episodically. Field priorities refresh at the pace of market reality. Lower‑tier hospitals become visible based on fragility and clinical risk rather than volume alone. Outcomes feed back into the system to refine future decisions.

This approach is not about creating more tools or governance forums. It is about deliberately designing how the organization acts under constraint before a crisis arrives.

When access is treated as infrastructure, reliability becomes repeatable rather than heroic.

Why Integrated “Execution infrastructure” Connects Strategy, Supply, and Patient Access in Generics

How Can AI Supplement this Approach?

Artificial intelligence plays an important role, but only when it is placed correctly.

AI is most effective at identifying early signals, including emerging demand shifts, supply vulnerabilities, substitution risk, and access friction. What it cannot do on its own is decide how an organization should respond across functions.

Execution infrastructure provides the context where AI becomes practical. Within a governed decision framework, AI can surface early access risks tied to specific hospitals or regions, simulate trade‑offs before allocation decisions are made, continuously learn which interventions reduce disruption, and shorten the time between signal and coordinated action.

In this role, AI supplements human judgment rather than replacing it. It improves speed, consistency, and learning while preserving accountability.

The real value lies not in prediction, but in operationalization.

Why Does This Shift Matter?

This perspective is shaped by years of working at the intersection of hospital markets, generics, supply volatility, and field execution.

Across organizations and portfolios, the same pattern repeats. Strategies are sound. Teams are capable. Data is available. Yet execution breaks down precisely when reliability matters most.

The lesson is clear. Access failures are rarely caused by a single bad decision. They emerge from systems that were never designed to act together under pressure.

Building execution infrastructure is not about technology for its own sake. It is about responsibility to hospitals that lack buffers, to clinicians managing uncertainty, and to patients whose care depends on continuity.

If the industry wants to move beyond managing shortages toward preventing their impact, it must stop treating access as an afterthought and start treating it as a core system capability.

Manufacturing matters. However, access determines whether medicines reach patients when they are needed most.

That outcome depends on how execution itself is designed.